Dr. Melissa A. Burgess
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Expert in Soft Tissue Sarcoma
Expert in Cancer
24 reported clinical trials
42 drugs studied
About Melissa A. Burgess
Education:
- Obtained a BS in Biochemistry & Molecular Biology and Chemistry from Dickinson College in 2005.
- Earned an MD from Drexel University College of Medicine in 2009.
- Completed Internal Medicine Residency at the University of Pittsburgh, UPMC (2009-2012).
- Finished Hematology/Oncology Fellowship at the University of Pittsburgh, UPMC (2012-2015), serving as Chief in 2014.
Experience:
- Serves as Assistant Professor of Medicine at the University of Pittsburgh School of Medicine.
- Acts as a Clinical and Translational Investigator in Sarcoma, with a focus on clinical trials.
- Holds the position of Local Principal Investigator for several clinical trials, including SARC 028 and CITN-09.
- Specializes in the treatment of soft tissue and bone sarcoma patients at the Hillman Cancer Center.
Area of expertise
1Soft Tissue Sarcoma
Global LeaderStage IV
Stage III
EWSR1/ATF1 positive
2Cancer
Global LeaderStage IV
EWSR1/ATF1 positive
EWSR1/CREB1 positive
Affiliated Hospitals
Clinical Trials Melissa A. Burgess is currently running
Atezolizumab +/− Selinexor
for Sarcoma
This trial is testing if atezolizumab alone or with selinexor can shrink tumors in patients with a rare type of cancer called alveolar soft part sarcoma. Atezolizumab boosts the immune system to fight cancer, and selinexor stops cancer cells from growing. The goal is to see if these treatments work better than the usual care.
Recruiting1 award Phase 2
Immunotherapy + Chemotherapy
for Soft Tissue Sarcoma
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Adding cabozantinib to the combination of ipilimumab and nivolumab may be better in stopping or slowing the growth of tumor compared to ipilimumab and nivolumab alone in patients with advanced soft tissue sarcoma.
Recruiting1 award Phase 2
More about Melissa A. Burgess
Clinical Trial Related5 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Melissa A. Burgess has experience with
- Nivolumab
- Atezolizumab
- Doxorubicin
- Dacarbazine
- Placebo
- Pembrolizumab
Breakdown of trials Melissa A. Burgess has run
Soft Tissue Sarcoma
Cancer
Skin Cancer
Parotid Gland Cancer
Uterine Leiomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Melissa A. Burgess specialize in?
Is Melissa A. Burgess currently recruiting for clinical trials?
Are there any treatments that Melissa A. Burgess has studied deeply?
What is the best way to schedule an appointment with Melissa A. Burgess?
What is the office address of Melissa A. Burgess?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.